Baidu
map

二步法切除术(ALPPS)用于传统意义上不可切除的肝硬化肝癌

2014-05-26 陶一明 罗闻 中国医学论坛报

中南大学湘雅医院肝脏外科王志明教授团队,采用世界肝脏外科最新技术,对1例原发性肝癌合并肝炎、肝硬化患者实施联合肝脏离断和门静脉结扎的“二步肝切除术”(ALPPS)获得成功。术后,患者康复良好并已于4月15日出院。据介绍,该手术的成功探索,为传统意义上不可切除的肝癌寻找到手术治疗的新途径。 据王志明介绍,2007年德国专家汉斯?施利特首创了ALPPS。该手术的原理是通过调整改变肝脏

中南大学湘雅医院肝脏外科王志明教授团队,采用世界肝脏外科最新技术,对1例原发性肝癌合并肝炎、肝硬化患者实施联合肝脏离断和门静脉结扎的“二步肝切除术”(ALPPS)获得成功。术后,患者康复良好并已于4月15日出院。据介绍,该手术的成功探索,为传统意义上不可切除的肝癌寻找到手术治疗的新途径。

据王志明介绍,2007年德国专家汉斯?施利特首创了ALPPS。该手术的原理是通过调整改变肝脏血流,促进正常肝组织再生,从而最大范围地切除肝肿瘤,提高切除率。

该院手术的患者有20多年乙型肝炎病史,其右肝前叶上段长有1枚鸡蛋大小的肿瘤,确诊为原发性肝癌合并肝炎、肝硬化。该患者的肿瘤如要达到根治性切除,必须将右半肝全切除。正常情况下,残留肝体积需达到标准肝体积的40%左右才能保证术后肝功能正常,而该患者的全肝体积仅800cm3(标准肝体积1237.5cm3),需要切除的肝体积为550cm3,剩余的体积仅占标准肝体积的20%,达不到手术切除的要求。王志明决定采用ALPPS技术救治患者。

王志明首先为患者实施右侧肝门静脉结扎术,以此减少右侧肝的血液供应,同时将左、右半肝劈开分离,保留了左侧门静脉和左、右侧肝动脉及肝内胆管。术后第6天,腹部CT检查显示,患者右侧肝体积因低血流量而缩小,左肝外叶体积得到快速增长,体积达到425.6cm3,占标准肝体积的34.4%,肝功能持续平稳。再过3天CT检查,左肝体积达到40%的“安全线”,符合开展第2次手术的安全标准。距第1次手术10天后,第2次手术实施,术者顺利将患者右半肝完整切除。

王志明表示,尽管所有接受过ALPPS的患者病情均有好转,但远期疗效仍需长期临床研究观察。

另外,该技术在华中科技在学附属同济医院也有较多开展。

相关文献:

Vennarecci G, Laurenzi A, Levi Sandri GB, Busi Rizzi E, Cristofaro M, Montalbano M, Piselli P, Andreoli A, D'Offizi G, Ettorre GM.The ALPPS procedure for hepatocellular carcinoma.Eur J Surg Oncol. 2014 Apr 13. pii: S0748-7983(14)00397-7.

Figueras J, Belghiti J.The ALPPS Approach: Should We Sacrifice Basic Therapeutic Rules in the Name of Innovation?World J Surg. 2014 Jun;38(6):1520-1.

Schadde E, Ardiles V, Slankamenac K, Tschuor C, Sergeant G, Amacker N, Baumgart J, Croome K, Hernandez-Alejandro R, Lang H, de Santibaňes E, Clavien PA.ALPPS Offers a Better Chance of Complete Resection in Patients with Primarily Unresectable Liver Tumors Compared with Conventional-Staged Hepatectomies: Results of a Multicenter Analysis.World J Surg. 2014 Jun;38(6):1510-9.

Zhang GQ, Zhang ZW, Lau WY, Chen XP.Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): A new strategy to increase resectability in liver surgery.Int J Surg. 2014;12(5):437-41.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977244, encodeId=27c019e72441e, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jan 30 22:56:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035975, encodeId=c0c120359e55d, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jun 25 11:56:00 CST 2014, time=2014-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876672, encodeId=818618e66726c, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 04 15:56:00 CST 2014, time=2014-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9605, encodeId=3df9960501, content=同济医院确实开展更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue May 27 09:28:00 CST 2014, time=2014-05-27, status=1, ipAttribution=)]
    2015-01-30 yyj062
  2. [GetPortalCommentsPageByObjectIdResponse(id=1977244, encodeId=27c019e72441e, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jan 30 22:56:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035975, encodeId=c0c120359e55d, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jun 25 11:56:00 CST 2014, time=2014-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876672, encodeId=818618e66726c, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 04 15:56:00 CST 2014, time=2014-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9605, encodeId=3df9960501, content=同济医院确实开展更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue May 27 09:28:00 CST 2014, time=2014-05-27, status=1, ipAttribution=)]
    2014-06-25 jiekemin
  3. [GetPortalCommentsPageByObjectIdResponse(id=1977244, encodeId=27c019e72441e, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jan 30 22:56:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035975, encodeId=c0c120359e55d, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jun 25 11:56:00 CST 2014, time=2014-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876672, encodeId=818618e66726c, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 04 15:56:00 CST 2014, time=2014-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9605, encodeId=3df9960501, content=同济医院确实开展更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue May 27 09:28:00 CST 2014, time=2014-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1977244, encodeId=27c019e72441e, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Fri Jan 30 22:56:00 CST 2015, time=2015-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035975, encodeId=c0c120359e55d, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jun 25 11:56:00 CST 2014, time=2014-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876672, encodeId=818618e66726c, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 04 15:56:00 CST 2014, time=2014-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9605, encodeId=3df9960501, content=同济医院确实开展更早, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue May 27 09:28:00 CST 2014, time=2014-05-27, status=1, ipAttribution=)]
    2014-05-27 lovetcm

    同济医院确实开展更早

    0

相关资讯

J Biol Chem:研究发现HCV损害肝脏的线索

       南加州大学的研究人员已经发现了丙型肝炎病毒进入肝细胞的触发机制——该机制揭示这种严重的和可能致命的病毒怎样开始损害肝脏。该研究结果,发表在生物化学杂志,这项研究可以给科学家指明今后病毒治疗的发展方向。        在丙型肝炎病毒(HCV)感染的早期阶段,研究人员发现,该病毒结合到肝细胞表面的受

以“阵发性心慌”为表现的一例老人患者

  典型病例   患者男,65岁,因“阵发性心慌”就诊。患者有高血压病史10年,规律服用氨氯地平5 mg/d,血压控制满意;乙肝病毒(HBV)感染病史30年,肝功能正常;2年前单位体检发现血糖略高,其余检查未见异常。无烟酒等嗜好。家族中父亲患食管癌,母亲患高血压,其兄患肺癌。平日体力活动正常、生活完全自理。近期独居。   入院检查   体胖,面色发黑,肝掌,

JAMA:核苷类似物可使HBV相关肝癌切除术后复发风险降低

      《美国医学会杂志》11月14日发表的一篇论文研究调查了核苷类似物的使用和乙肝病毒(HBV)相关肝细胞癌肝切除后复发风险。   对HBV相关肝癌肝脏切除后的病人来说,肿瘤复发是主要问题。   中国台湾的Chun-Ying Wu医生和同事研究了核苷类似物的使用和HBV相关肝细胞癌根治性手术后肿瘤复发风险。   研究者对2003年和

J NATL CANCER I:阿司匹林或可预防肝癌

       非甾体抗炎药,尤其是阿司匹林,可以预防严重的肝脏问题,一项大型的观测研究建议。       服用阿司匹林的人中,相对非使用者,41%发展为肝癌的可能性更小,45%死于慢性肝脏疾病可能性更小,他们之间都存在显着差异,美国国家癌症研究所Vikrant V. Sahasrabuddhe和同事报告。其他非甾体抗炎

J CANCER RES CLIN:部分进展期肝癌仍可手术

       上海第二军医大学东方肝胆外科医院杨田等近期发表的一项回顾性分析表明,根据国际认可的巴塞罗那分期(BCLC)判断为进展期(C 期)的肝细胞癌患者,在肿瘤可切除、肝功能储备良好和剩余肝体积足够的情况下,仍可考虑外科手术治疗。        该研究纳入了2001-2007 年收治的511 例判定为BC

Int J Cancer:索拉非尼可结合动脉栓塞治疗肝肿瘤

       肝动脉栓塞化疗(Transcatheter Arterial Chemoembolization,TACE)的同时给予索拉非尼对于中期肝癌(HCC)患者是安全的,不会导致任何意外的不良影响,根据在韩国,中国,和台湾的第二阶段试验的结果显示。        “除了鼓舞人心的安全性和耐受性的结果,我

Baidu
map
Baidu
map
Baidu
map